Domainex Ltd has developed a number of chemical series with potent and selective activity against two closely related kinases TBK1 and IKK- epsilon.
5th November 2012
6th August 2012
Domainex and Horizon announce collaboration in support of Domainex's TBK1/IKKe Inhibitor Program.
2nd August 2012
Domainex successful in securing Biomedical Catalyst Feasibility Award
12th March 2012
Combinatorial domain hunting technology aids identification of MEK protein suitable for structure-based drug discovery New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK
6th January 2012
Download Press release
29th November 2011
Domainex to Present at a Range of Industry Events in December 2011, including Epigenetics Summit in Munich, including:
8th November 2011
This is to recognise its work on the development of a new cancer drug against the novel kinase targets TBK1/IKKe.
1st November 2011
Domainex has been awarded a £250,000 grant by the Technology Strategy Board to support development of a new drug for treatment of several common cancers.
1st October 2011
Chemical & Engineering News (External link)
6th April 2011
Cambridge Business Media Interview (External link)